NeoGenomics provided preliminary Q3 2023 revenue of approximately $209 million, which is above the high end of their previous guidance. The company also reiterated its FY2026 revenue and adjusted EBITDA guidance, indicating confidence in long-term growth, and expects to raise the midpoint of its FY2026 revenue guidance during its Q3 earnings call.
NeoGenomics announced preliminary Q3 2023 revenue of approximately $209 million, exceeding the previously guided range of $200 million to $205 million. This strong performance suggests better-than-expected operational execution in the short term. The company also reiterated its ambitious FY2026 revenue and adjusted EBITDA guidance, and importantly, expects to raise the midpoint of its FY2026 revenue guidance on the upcoming Q3 call. This indicates sustained confidence in its long-term growth trajectory and could lead to positive analyst revisions and investor sentiment. For traders, this presents a short-term opportunity for a positive price reaction for NEO, with the long-term outlook also appearing more robust.